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Introduction: The two isoforms of estrogen receptor (ER) alpha and beta play opposite roles in regulating
proliferation and differentiation of breast cancers, with ER-alpha mediating mitogenic effects and ER-beta acting
as a tumor suppressor. Emerging data have reported that androgen receptor (AR) activation inhibits ER-positive
breast cancer progression mainly by antagonizing ER-alpha signaling. However, to date no studies have specifically
evaluated a potential involvement of ER-beta in the inhibitory effects of androgens.
Methods: ER-beta expression was examined in human breast cancer cell lines using real-time PCR, Western blotting
and small interfering RNA (siRNA) assays. Mutagenesis studies, electromobility shift assay (EMSA) and chromatin
immunoprecipitation (ChIP) analysis were performed to assess the effects of mibolerone/AR on ER-beta promoter
activity and binding.
Results: In this study, we demonstrate that mibolerone, a synthetic androgen ligand, up-regulates ER-beta mRNA
and protein levels in ER-positive breast cancer cells. Transient transfection experiments, using a vector containing
the human ER-beta promoter region, show that mibolerone increases basal ER-beta promoter activity. Site-directed
mutagenesis and deletion analysis reveal that an androgen response element (ARE), TGTTCT motif located at
positions −383 and −377, is critical for mibolerone-induced ER-beta up-regulation in breast cancer cells. This
occurs through an increased recruitment of AR to the ARE site within the ER-beta promoter region, along with
an enhanced occupancy of RNA polymerase II. Finally, silencing of ER-beta gene expression by RNA interference is
able to partially reverse the effects of mibolerone on cell proliferation, p21 and cyclin D1 expression.
Conclusions: Collectively, these data provide evidence for a novel mechanism by which activated AR, through an
up-regulation of ER-beta gene expression, inhibits breast cancer cell growth.Introduction
Sex steroid hormones are critical for the development and
progression of endocrine-dependent diseases, including
breast cancers. Estrogen and androgen hormone signals
are transduced via the action of specific members of a
superfamily of nuclear steroid receptors that, functioning
as ligand-activated transcription factors, are able to inter-
act with a host of different coregulators to regulate gene
transcription.
The roles of estrogen receptor (ER) alpha and beta
in breast cancer pathogenesis are becoming increasingly* Correspondence: sebastiano.ando@unical.it
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reproduction in any medium, provided the orelucidated by several clinical and in vitro studies. ER
alpha mediates cancer-promoting effects of estrogen and
has been shown to be an effective therapeutic target for
decades [1]. In contrast, ER beta has a well known growth
and invasion inhibitory activity in ERα-positive breast can-
cer cells, at least in part due to ER beta’s inhibition of ER
alpha selective target gene expression, and can be consid-
ered as an endogenous partial dominant negative receptor
[2,3]. Indeed, the progression of breast cancer is associated
with a change in the expression ratio of the isoforms of
ER, with ER alpha the predominant isoform expressed [4].
Moreover, compared with tumors expressing ER alpha
alone, the co-expression of ER beta has been correlated
with a more favorable prognosis [5] and decreased
biological aggressiveness [6-9].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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been described in human breast cancers both in vivo
and in vitro, but considerably less is known on their
impact on this disease. Emerging evidence indicates that
the androgen signaling pathway mainly exerts inhibitory
effects on the growth of normal mammary epithelial
cells and plays a protective role in the pathogenesis of
breast cancer [10-13]. In particular, AR is present in
approximately 70% to 90% of invasive breast carcinomas,
a percentage equal to or higher than that of ER (70% to
80%) and its expression shows significant association
with favorable clinicopathological characteristics, such as
lower tumor grade, smaller tumor size, better outcomes
and improved response to hormone therapy in ER-
positive breast cancers [14-18]. In vitro studies have
demonstrated that androgen signaling may counteract
the proliferative effect of estrogens in AR-positive breast
cancer cells [19], while over-expression of the AR mark-
edly decreases ER alpha transcriptional activity in ER-
positive breast cancer cells [20,21]. In these latter
models, basal as well as estradiol-induced proliferation
are inhibited by the non-aromatizable androgen 5-
a-dihydrotestosterone (DHT) [21-23], through an in-
crease in AR protein cell content [21], along with a
block in G1 to S transition of the cell cycle [21,22].
AR-induced apoptosis has also been reported in
these cell lines [24]. Recently, we have shown a direct
down-regulation of the cyclin D1 gene expression by
AR activation via interaction with the orphan nuclear
receptor DAX1, as an additional mechanism involved
in the androgen-dependent inhibition of ER-positive
breast cancer cell growth [25].
Given the ability of AR to function as an anti-pro-
liferative effecter by antagonizing ERα signaling [26],
the aim of this study was to investigate whether ER
beta may also be a target of androgen actions. Here,
we demonstrate that mibolerone, a synthetic non-
metabolizable androgen, up-regulates ER beta expres-
sion and gene promoter activity, through a direct
binding of AR to a newly identified androgen response




Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture
F-12 Ham, DMEM, 100 bp DNA ladder, l-glutamine,
penicillin, streptomycin, bovine serum albumin and
phosphate-buffered saline were purchased from Invitrogen
(Carlsbad, CA, USA), and Sephadex G50 spin columns
and poly (dI-dC) from Roche (Indianapolis, IN, USA).
GoTaq DNA polymerase, T4 polynucleotide kinase, dual
luciferase kit, FuGENE 6 and CMV renilla luciferase
plasmid were provided by Promega (Madison, WI, USA).The RETROscript kit and DNase I were purchased from
Ambion (Austin, TX, USA). Aprotinin, leupeptin, phenyl-
methylsulfonyl fluoride, sodium orthovanadate, formal-
dehyde, NP-40, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT), dimethyl sulfoxide, protein-
ase K, tRNA, IGF-1, DHT, bicatulamide(Cx) were from
Sigma (Milan, Italy). Antibodies against cyclin D1, p21,
GAPDH, and polymerase II (N20) were provided by Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Antibody anti-
ER beta (clone 64–4, rabbit monoclonal immuno-
globulin G (IgG), 1:1000 dilution) was purchased from
Millipore. The ECL System, 3H thymidine and [γ32P]
ATP were purchased from PerkinElmer (Wellesley,
MA, USA), salmon sperm DNA/protein A agarose was
from UBI (Chicago, IL, USA), and triazol, SYBR Green
Universal PCR Master Mix was from Biosystems (Forster
City, CA, USA).Cell cultures
The three human breast cancer cell lines MCF-7, ZR-75
and MDA-MD 231 were acquired in 2010 from American
Type Culture Collection (ATCC, Manassas, VA, USA)
where they were authenticated, stored according to the
supplier’s instructions, and used within a month after fro-
zen aliquots were resuscitated. MCF-7 cells were cultured
in DMEM-F12 containing 5% fetal bovine serum (FBS),
1% l-glutamine and 1 mg/ml penicillin–streptomycin.
ZR-75 cells were maintained in DMEM supplemented
with 10% FBS, 1% l-glutamine and 1 mg/ml penicil-
lin–streptomycin. MDA-MB- 231 cells were cultured in
DMEM containing 5% FBS, 1% l-glutamine and 1 mg/ml
penicillin–streptomycin.
Every four months cells were authenticated by single tan-
dem repeat analysis at our Sequencing Core; morphology,
doubling times, estrogen sensitivity, and mycoplasma negativ-
ity were tested (MycoAlert™, Lonza, Walkersville, MD, USA).Plasmids
The plasmids containing the human ER beta pro-
moter 0 N region or its deletions (A: p − 1568/+315;
B: p − 1283/+315, D: p − 355/+315) were a gift from
Prof. Karin Dahlman-Wright (Department of Biosci-
ences and Nutrition, Karolinska Institute, Sweden). C
plasmid (p-400/+315) and mutated on ARE site C
plasmid (M ARE mut) were generated by PCR using
the following primers: forward 5′- ATATACGCGTAA
TCAGACATCTGTTCTGAATGACACTTATGTGAG −3′
and reverse 5′- ATATCTCGAGCGAAGGGGCGCTT
ACC −3′; forward 5′- ATATACGCGTAATCAGACA
TCTACCCTGAATGACACTTATGTG-3′. The amplified
DNA fragments were digested with Mlu I and Xho I and
ligated into pGL3-basic vector. The sequences were con-
firmed by nucleotide sequence analysis.
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Cells were treated as indicated before lysis. Equal amounts
of cell extracts were subjected to SDS-PAGE, as described
previously [27,28]. Blots are representative of at least three
independent experiments.
Real-time RT-PCR
The gene expression of ER beta, cyclin D1, p21 and GAPDH
was evaluated by real-time RT-PCR. Total RNA was reverse
transcribed with RETROscript kit. Diluted (1:3) cDNA (5 μl)
was analyzed in triplicate by real-time PCR in an iCycler iQ
Detection System (Bio-Rad, Hercules, California, USA)
using SYBR Green Universal PCR Master Mix, following
the manufacturer’s recommendations. Each sample was
normalized on its GAPDH mRNA content. Primers used
for the amplification were: forward 5′-CCCTGCTGTG
ATGAATTACAG −3′ and reverse 5′- TCGGTTCCCACT
AACCTTCC-3′ (ER beta); forward 5–GCATGACAGA
TTTCTACCACTCC-3′ and reverse 5′-AAGATGTAGA
GCGGGCCTTT-3′ (p21); forward 5′-CTGGAGGTCTG
CGAGGAA-3′ and reverse 5′-GGGGATGGTCTCCTT
CATCT-3′ (CYCD1); forward 5′-CCCACTCCTCCACCTT
TGAC-3′ and reverse 5′-TGTTGCTGTAGCCAAATTC
GTT-3′ (GAPDH). The relative gene expression levels were
calculated as described [29].
Transient transfection assays
MCF-7 cells were transiently transfected using the
FuGENE 6 reagent with ER beta gene promoter, differ-
ent deleted segments, and M ARE mut and treated as
indicated. Empty vectors were used to ensure that DNA
concentrations were constant in each transfection. Lucif-
erase activities were assayed using the Dual Luciferase
assay system (Promega) [30,31].
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from MCF-7 cells
treated with vehicle or mibolerone 10 nM for 16 hours
as previously described [32,33]. The DNA sequences
used as probe or as cold competitor are the following
(mutations are shown as lowercase letters): 5′- AGAAT
CAGACATCTGTTCTGA ATGACA −3′, 5′ T GTCAT
TCAGAACAGATGTCTGATTCT-3′ (ARE); 5′- AGA A
TCAGACATCTaccCTGAATGACA-3′, 5′- TGTCATT
CAGggtAGATGTCTGATTCT −3 (mutated ARE). Probe
generation and the protein-binding reactions were carried
out as described [34]. For experiments involving anti-
bodies, the reaction mixture was incubated with AR or
IgG antibodies at 4°C for 12 hours before addition of
labeled probe.
RNA interference (RNAi)
MCF-7 cells were transfected with RNA duplex of stealth
RNA interference (RNAi)-targeted for human ER betamRNA sequence 5′-CACUUCUGCGCUGUCUGCAGC
GAUU −3′ (Life Science, Hercules, California, USA) or
with a stealth RNAi-negative control (Life Science) to a
final concentration of 100 nM using Lipofectamine 2000
as recommended by the manufacturer [35,36].
Chromatin immunoprecipitation assays
Cells were treated with vehicle or mibolerone 10 nM
and after 16 hours the DNA/protein complexes were
extracted as previously described [37]. The precleared
chromatin was immunoprecipitated with anti-AR and
anti-poymerase II antibodies. A normal mouse serum
IgG was used as negative control. For each sample and
input DNA, 5 μl were used for PCR amplification with
the following primers flanking ARE sequence present in
the ER beta promoter region: 5′- GGTTTCACCACT
GGCTCCTT-3′ (forward) and 5′-ACTGATACAGCCA
GTCTGGG-3′ (reverse). Final results were calculated
using the ΔΔ Ct method, using input Ct values instead
of the GAPDH mRNA. The basal sample was used as
calibrator.
Cell proliferation assays
Cell proliferation was determined by using the MTT
assay as previously described [38] Data are representa-
tive of three independent experiments, each performed
in triplicate. For [3H]thymidine incorporation, a total of
1 × 105 cells was seeded onto 12-well plates in complete
medium and then treated as indicated. Control (−) cells
were treated with the same amount of vehicle alone
(dimethylsulfoxide (DMSO)) that never exceeded a con-
centration of 0.01% (v/v). [3H]Thymidine incorporation
was evaluated after a 24-hour incubation period with
1 μCi of [3H]thymidine per well. Cells were washed once
with 10% trichloroacetic acid, twice with 5% trichlo-
roacetic acid, and lysed in 1 ml of 0.1 M NaOH at 37°C
for 30 minutes. The total suspension was added to 10 ml
of Optifluor fluid and was counted in a scintillation
counter.
Statistical analysis
Data were analyzed for statistical significance using a two-
tailed Student’s t-test, performed by Graph Pad Prism 4.
Standard deviations (S.D.) are shown.
Results
Mibolerone increases ER beta expression in breast cancer
cells
We have previously demonstrated that the non-aromatiz-
able androgen DHT decreased cell proliferation in a dose-
dependent manner in ER-positive MCF-7 breast cancer
cells [21,26]. In this study, to minimize the metabolic con-
version of androgen to estrogenic compounds by cultured
cells, we used the synthetic non-metabolizable androgen
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http://breast-cancer-research.com/content/16/1/R21mibolerone to test its effects on cell proliferation by meas-
uring changes in the rate of DNA synthesis (3H thymidine
incorporation). We found similar inhibitory effects on the
proliferation of ER-positive MCF-7 and ZR 75 breast
cancer cells after two, four and six days of mibolerone
treatment (Figure 1A). Given the known tumor repressive
role of ER beta in breast cancer cell lines, we wondered
whether AR also functions as an anti-proliferative effector
in ER-positive breast cancer by affecting ER beta expres-
sion. First, MCF-7 and ZR75 breast cancer cells were
treated with mibolerone for 24 and 48 hours and ER beta
mRNA and protein levels were evaluated by real time
RT-PCR and western blotting analysis. As shown in
Figure 1B and C, mibolerone treatment increased ER
beta expression at all times investigated in both MCF-7
and ZR75 cells.
Clear evidence of the crucial role of AR in mediating
these effects has been pointed out by the fact that the
AR inhibitor hydroxyflutamide (OH-Fl) completely re-
versed the up-regulation of ER beta mRNA and protein
content induced by mibolerone (Figure 2A and B). It







































































































   
   











Figure 1 Mibolerone up-regulates ER beta expression in breast cance
treated with vehicle (−) or mibolerone (Mib) 10 nM for two, four and six da
with triplicate samples expressed as percent of control. (B) Total RNA was
10 nM for 24 and 48 hours, and reverse transcribed. cDNA was subjected t
sample was normalized to its GAPDH mRNA content. Data represent the m
percentage of control assumed to be 100%. (C) Bottom panel, Western blo
and ZR75 cells, treated with vehicle (−) or Mib 10 nM for 24 and 48 hours.
represent the mean ± S.D. of three independent experiments in which ban
and expressed as the percentage of the control assumed to be 100%. *, Pligand, DHT, and an androgen antagonist, bicatulamide,
we observed similar results on ER beta expression
(Additional file 1: Figure S1B and S1C). Accordingly,
bicalutamide reversed the inhibition mediated by both
mibolerone and DHT on MCF-7 and ZR-75 cell growth
(Additional file 1: Figure S1A).
Activated AR up-regulates ER beta via an ARE site of its
promoter
To analyze if mibolerone might positively modulate ER
beta gene transcription, MCF-7 and ZR75 breast cancer
cell lines were transiently transfected with a luciferase
reporter plasmid containing the human ER beta promoter
region spanning from −1568 bp to +315 bp. As shown in
Figure 3A, a significant increase in ER beta promoter
activity was observed in cells treated with mibolerone,
while this induction was abrogated in the presence of the
AR inhibitor OH-Fl (Figure 3A). The human ER beta
promoter contains multiple consensus sites for several
transcription factors, including an AP-1 box, OCT-1,
GATA, and ARE [39]. To identify the regions within the





































































































   
   













r cells. (A) 3H Thymidine incorporation assays in MCF-7 and ZR-75 cells
ys. Columns, mean of three independent experiments, each performed
isolated from MCF-7 and ZR75 cells treated with vehicle (−) or Mib
o real time PCR using specific primers for ER beta and GAPDH. Each
ean ± S.D. of values from three separate RNA samples expressed as a
t analysis of ER beta expression in total protein extracts from MCF-7
GAPDH was used as loading control. Upper panel, the histograms
d intensities were evaluated in terms of optical density arbitrary units

















































































































































































Figure 2 Hydroxyflutamide (OH-Fl) reverses mibolerone’s effects on ER beta expression. (A) Real-Time RT-PCR for analyzing ER beta mRNA
levels in cells treated as indicated. Each sample was normalized to GAPDH RNA content. Data represent the mean ± S.D. of values from three
separate RNA samples expressed as the percentage of control assumed to be 100%. (B) Bottom panel, Western blot analysis of ER beta expression
in cells treated with vehicle (−) or Mib 10 nM in the presence or absence of OH-Fl 1 μM for 48 hours. GAPDH was used as loading control. Upper
panel, the histograms represent the mean ± S.D. of three independent experiments in which band intensities were evaluated in terms of optical
density arbitrary units and expressed as the percentage of the control assumed to be 100%. *, P <0.01 compared to vehicle treated-cells. **, P <0.01
compared to Mib treated cells. ER, estrogen receptor.
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http://breast-cancer-research.com/content/16/1/R21stimulatory effects, we transiently transfected both MCF-7
and ZR-75 cell lines with plasmids containing a series of
5′deleted segments of the human ER beta promoter.
Schematic representation of these constructs is shown in
Figure 3B. In transfection experiments performed using
p-1568/+315 (A), p1256−/+315 (B) and p-400/+315
(C) plasmids, the responsiveness to mibolerone was
still maintained (Figure 3B), suggesting that the region
between −400 to +315 might be involved in the trans-
activation mechanisms exerted by mibolerone. Thus, we
focused our attention on the latter construct, p-400/+315
(C), and we identified, upstream to the initiation transcrip-
tion site, one ARE site, which is the putative effector of
AR signaling. We observed that in MCF-7 cells transiently
transfected with the ER beta promoter plasmid bearing
the ARE-mutated site or with a deleted construct of ER
beta promoter without the ARE site (p-355/+315, D),
mibolerone was no longer able to induce ER beta pro-
moter activity (Figure 3C). Similar results were obtained
in ZR75 breast cancer cells (data not shown). Taken to-
gether, our findings demonstrated that the up-regulatoryeffects exerted by mibolerone on ERβ promoter gene
expression require an ARE sequence motif.
The AR protein is recruited at an ARE site to ER beta
promoter region
The specific role of the ARE motif in mediating the
stimulatory role of mibolerone on ER beta gene expression
was then investigated using EMSAs and chromatin immu-
noprecipitation (ChIP) assays. Using synthetic radiola-
beled oligonucleotides bearing the ARE site present in the
ER beta promoter region (Figure 4A, lane 1), we observed
the formation of a protein complex in nuclear extracts
from MCF-7 cells, which was abrogated by incubation
with 100-fold molar excess of unlabeled probe (Figure 4A,
lane 2), demonstrating the specificity of the DNA-binding
complex. This inhibition was no longer observed when a
mutated oligodeoxyribonucleotide probe was used as
a competitor (Figure 4A, lane 3). Interestingly, treat-
ment with mibolerone strongly increased the DNA-
binding protein complex compared with control samples
(Figure 4A, lane 4). The inclusion of the anti-AR antibody






































Luciferase activity (Fold Change) Luciferase activity (Fold Change)













































































Figure 3 ER beta promoter activity is up-regulated by mibolerone through an ARE site. (A) Upper panel, schematic representation of
construct of the ER beta gene promoter used in this study. Bottom panel, plasmid containing ER beta promoter fragment was transiently
transfected in MCF-7 and ZR-75 cells treated with vehicle (−) or Mib 10 nM in the presence or absence of 1 μM OH-Fl. *, P <0.05 compared to
vehicle-treated cells; *, P <0.05 compared to Mib-treated cells. (B, C) Left panel, schematic representation of constructs of the ER beta gene
promoter used in this study. Right panel, plasmids containing ER beta promoter fragments were transiently transfected in cells treated with
vehicle (−) or Mib 10 nM. After 24 hours of transfection, luciferase activities were normalized to the Renilla Luciferase as the internal transfection
control and data were reported as fold change. The values represent the means ± S.D. of three different experiments each performed in triplicate.
pGL3: basal activity measured in cells transfected with pGL3 basal vector. *, P <0.05 compared to vehicle-treated cells; *, P <0.05 compared to
Mib-treated cells. ARE, androgen response element; ER, estrogen receptor.
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http://breast-cancer-research.com/content/16/1/R21in the reaction supershifted the specific band, confirming
the presence of this protein in the complex (Figure 4A,
lanes 5). Non specific IgG did not affect AR complex
formation (Figure 4A, lane 6).
Moreover, to better evaluate the functional importance
of the ARE site at the ER beta promoter level, ChIP
assays were performed. Protein-chromatin complexes
were immunoprecipitated from MCF-7 cells treated with
mibolerone using specific antibodies against AR or RNA-polymerase II (Figure 4B and C). Real-time PCR using
primers spanning the AR binding element in the ER
beta promoter region clearly showed an enhanced re-
cruitment of AR upon treatment with mibolerone.
These results were concomitant with an increased asso-
ciation of RNA-polymerase II to the ER beta regulatory
region (Figure 4C), indicating that the chromatin in this


































































Competitor (100 fold excess)
Ab-AR
IgG
Figure 4 Mibolerone recruits AR protein to an ARE site in the ER beta gene promoter. (A) Nuclear extracts from MCF-7 cells treated with
vehicle (−) or Mib 10 nM for 16 hours were incubated with a double-stranded ARE specific sequence probe labeled with [γ32P] ATP and subjected
to electrophoresis in a 6% polyacrylamide gel (lanes 1 and 4). Competition experiments were performed adding as the competitor a 100-fold
molar excess of unlabeled probe (lane 2 ) or a 100-fold molar excess of unlabeled oligonucleotide containing a mutated ARE motif (lane 3).
Nuclear extracts from MCF-7 cells treated with Mib 10 nM for 16 hours were incubated with anti-AR (lane 5) or IgG (lane 6) antibodies, in the
presence of the probe. Lane 7, probe alone. (B,C), MCF-7 cells treated with vehicle (−) or Mib 10 nM for 16 hours were cross-linked with formaldehyde
and lysed. The pre-cleared chromatin was immune-precipitated with specific anti-AR, anti-polymerase II antibodies, and with a normal mouse serum
(IgG) as a negative control. For each sample and input, a 5 μl volume was analyzed by real time PCR with specific primers, as detailed in the Methods
Section, to amplify the ER beta promoter sequence containing the ARE site. The histograms represent the mean ± S.D. of three independent
experiments. *, P <0.05 compared to vehicle-treated cells; *, P <0.01 compared to Mib-treated cells. AR, androgen receptor; ARE, androgen
response element; ER, estrogen receptor; IgG, immunoglobulin G.
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breast cancer cells
To extend the results obtained, we also evaluated the
effects of mibolerone on ER beta expression in the ER
alpha-negative, ER beta-positive MDA-MB-231 breast
cancer cell line. As previously shown for MCF-7 and
ZR-75 cells, treatment with mibolerone for 48 hours
enhanced ER beta mRNA and protein levels that were
completely reversed in the presence of the androgen
antagonist OH-Fl (Figure 5A and B). Again, treatment
with mibolerone significantly increased ER beta pro-
moter activity and this induction was abrogated both
in cells treated with OH-Fl and in cells transfected with
the ER beta promoter plasmid bearing the ARE mutated
site (M ARE mut) (Figure 5C). Therefore, AR activation
resulted in an up-regulation of ER beta expression and
activity in different cellular backgrounds.ER beta knockdown reverses mibolerone’s effects on cell
proliferation
Since the anti-proliferative effects of ER beta have been
associated with a repression of cyclin D1 expression and
activation of growth-inhibitory genes, such as p21 (WAF1)
[40], and these genes are important in mediating AR inhi-
bitory signaling [41], we aimed to examine whether ER
beta may be involved in modulation of the expression of
p21 and cyclin D1 induced by mibolerone.
To this aim, ER beta siRNA knockdown experiments
were performed in both MCF-7 and ZR-75 breast cancer
cells treated with mibolerone. As expected, mibolerone
treatment induced an increase of p21 expression along
with a reduction of cyclin D1 expression. Silencing of
ER beta gene expression (evaluated by Western blot,
Additional file 2: Figure S2) counteracted at least in part



































































































































Figure 5 Mibolerone increases ER beta expression in MDA-MB-231 breast cancer cells. (A) Real-time PCR for ER beta mRNA expression in
cells treated with vehicle (−) or mibolerone (Mib) 10 nM in the presence or absence of OH-Fl for 48 hours. Each sample was normalized for its
GAPDH mRNA content. Data represent the mean ± S.D. of values from three separate RNA samples expressed as the percentage of the control
assumed to be 100%. (B) Bottom panel, Western blot analysis of ER beta in total protein extracts from cells treated with vehicle (−) or Mib 10 nM
in the presence or absence of OH-Fl for 48 hours. GAPDH was used as loading control. Upper panel, the histograms represent the mean ± S.D. of
three independent experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as the percentage
of the control assumed to be 100%. (C) ER beta luciferase promoter activity in cells transfected and treated as indicated. The values represent the
means ± S.D. of three different experiments each performed in triplicate. *, P <0.05 compared to vehicle-treated cells. **, P <0.05 compared to
Mib-treated cells. ER, estrogen receptor.
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http://breast-cancer-research.com/content/16/1/R21at both the mRNA and protein levels. No changes were
observed after transfection of cells with a scrambled
siRNA control (Figure 6A and B). Accordingly, ER beta
gene silencing partially reversed the inhibition medi-
ated by mibolerone on MCF-7 and ZR-75 cell growth
(Figure 6C and E), suggesting how the anti-proliferative
effects exerted by mibolerone may also be related to an
induction of ER beta levels.
Discussion
In this study, we show, for the first time, that androgens
increase ER beta gene expression in ERα-positive breast
cancer cells. This occurs through an enhanced recruit-
ment of AR to the ARE site located at −383 to −377 bpup-stream of the initiating transcription site within the
human ER beta promoter region (Figure 7).
The ER expression is a well established marker in
clinical practice, reflecting the biology of the tumor, the
prognosis and the prediction of responsiveness to endo-
crine therapy [42,43]. However, the clinical significance
of other endocrine-related pathways such as androgen
and AR signaling has been recently proposed in primary
breast cancer patients [44]. Indeed, several studies
have suggested that AR expression correlates with
favorable clinicopathological characteristics at diagno-
sis, including lower histologic grade, smaller tumor
size, negative nodal status and ER positivity, and
better outcomes among study populations as a whole
p21
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Figure 6 ER beta silencing counteracts the effects of mibolerone on p21, cyclin D1 expression and cell proliferation. (A) RNA was
extracted from MCF-7 cells treated with vehicle (−) or Mib 10 nM for 48 hours in the presence of a non-specific or an ER beta siRNA, reverse
transcribed and cDNA was subjected to Real-Time RT-PCR for p21 and cyclin D1 mRNA expression. Each sample was normalized to GAPDH mRNA
content. Data represent the mean ± S.D. of values from three separate RNA samples expressed as the percentage of the control (−) assumed to
be 100%. (B) Western blot analysis for p21 and cyclin D1 expression in cells treated with vehicle (−) or Mib for 48 hours in the presence of a
non-specific or an ER beta siRNA. GAPDH was used as the loading control. The histograms represent the mean ± S.D. of three independent
experiments in which band intensities were evaluated in terms of optical density arbitrary units and expressed as the percentage of the control
assumed to be 100%. (C, D) MTT assays in MCF-7 and ZR-75 cells transfected and treated as indicated. Results are expressed as fold change ± S.D
and are representative of three different experiments each performed in triplicate. *, P <0.01 compared to vehicle-treated cells. **, P <0.01 ER beta
siRNA-transfected cells compared to Mib-treated cells. ER, estrogen receptor; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.
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alone [45,46]. Despite the growing evidence highlight-
ing the potential prognostic and/or predictive role of
AR in breast cancer, the mechanisms by which an-
drogen signaling may affect tumor progression still
remain not well clarified.
Several in vitro studies suggest that androgens may exert
a divergent role in breast cancer cells [47]. For instance, ithas been demonstrated that AR cooperates with ERs at
the non-transcriptional level leading to Src activation and
stimulation of DNA synthesis [48-50]. Nevertheless, most
in vitro and in vivo studies indicate that activated AR
exerts an anti-estrogenic, growth-inhibitory influence in
ERα-positive luminal breast cancers, partly dependent on
its ability to antagonize ERα signaling through several
mechanisms [51,52].
Figure 7 Proposed working model of the AR-mediated regulation of ER beta expression in breast cancer cell lines. In MCF-7 and ZR-75
cells, upon mibolerone treatment, AR is recruited on the ARE-containing region of ER beta promoter, leading to an increase in ER beta expression
and resulting in an inhibition of tumor growth progression. AR, androgen receptor; ARE, androgen response element; ER, estrogen receptor.
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potential crosstalk between AR and ER beta. Here, we
have demonstrated that treatment with the synthetic
non-metabolizable androgen mibolerone induced an in-
crease of ER beta expression both in terms of mRNA
levels and protein content in MCF-7 and ZR-75 breast
cancer cells. These effects are completely reversed by
the AR inhibitor OH-flutamide, confirming the role of
AR in the up-regulation of ER beta mediated by miboler-
one. We also reproduced similar results in ER alpha
negative, ER beta positive breast cancer cells MDA-MB-
231 suggesting that the action of androgens on ER
beta expression may represent a general mechanism not
related to cell specificity.
In humans, different isoforms of the ER beta mRNA
which diverge in their 5′-untranslated regions were
identified [53]. They were generated by alternative spli-
cing of two upstream exons, exon 0 K and exon 0 N, to
exon 1, indicating that transcription of the human ER
beta gene occurs from at least two different promoters.
The ER beta gene promoter 0 N has been cloned and
characterized [39]. Sequence analysis of the 5′-flanking
region of ER beta promoter 0 N has shown the presence
of several consensus transcriptional factor binding sites
and cis regulatory elements [39], including an AP-1 box,
OCT-1, GATA, and ARE. AREs are defined as chromo-
somal regions to which the AR is recruited in order to
modulate gene expression in an androgen-dependent
manner [54] Although the sequence 5′-AGAACAnnn
TGTTGT-3′ has been described as the canonical ARE
presenting an inverted repeat [55], different studiesrevealed that AREs can significantly differ from this
‘classical’ sequence [56]. For instance, AREs can be ar-
ranged as direct repeats and differences in the sequence
and arrangement of AR-binding sites have been described
which seem to mediate variable affinity and specificity of
AR [57,58]. Indeed, ChIP-on-chip data revealed that the
AR binds to genomic regions that contain DNA elements
which might consist of simple 5′-TGTTCT-3′-like mono-
mer binding sites [54,59,60]. Our functional experiments
using ER beta promoter-deleted or mutated constructs
have shown that the ARE sequence is an important pre-
requisite for the up-regulatory effects of mibolerone on
ER beta promoter activity. These results were well sup-
ported by electrophoretic mobility shift assays, which re-
vealed a marked increase in a specific DNA-binding
complex in nuclear extracts from MCF-7 cells treated
with mibolerone. This complex was immune-supershifted
by an anti-AR antibody, indicating the presence of AR in
the complex. Furthermore, ChIP analysis clearly showed
an enhanced recruitment of AR to the ARE site within ER
beta gene promoter, that was concomitant with an in-
crease in RNA polymerase II occupancy, supporting the
positive role for mibolerone in inducing ER beta gene
transcriptional machinery.
ER beta has been shown to inhibit human breast
cancer cell proliferation by repressing transcription of
the c-myc, cyclin D1 and cyclin A genes and increasing
the expression of the cyclin-dependent kinase inhibitors
p21Waf1/Cip1 and p27Kip1, leading to cell cycle arrest in
the G2 phase [5,40,61]. Moreover, p21 up-regulation
and cyclin D1 down-regulation have been identified as
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In accordance with these findings, we demonstrate that
silencing of ER beta gene expression reduced both
protein and mRNA expression of p21 induced by mibo-
lerone, while it increased both protein and mRNA expres-
sion of cyclin D1 reduced by mibolerone. In addition, the
anti-proliferative effects exerted by androgens were par-
tially reversed in the presence of ER beta siRNA knock-
down in both MCF-7 and ZR-75 breast cancer cells,
suggesting how the growth inhibitory effects exerted
by mibolerone may also be related to an induction of
ER beta levels.
Conclusions
We suggest that induction of ER beta expression by mibo-
lerone may play a critical regulatory role in ER-positive
cells, addressing prospectively that combined agents able
to potentiate ER beta and AR signalings may be useful to
inhibit breast cancer cell growth and progression.
Additional files
Additional file 1: Figure S1. Hydroxyflutamide (OH-Fl) and
Bicatulamide (Cx) reverse mibolerone’s or DHT's effects on cell
proliferation and ER beta expression in breast cancer cells. (A) MCF-7 and
ZR-75 cells were treated for six days with the indicated concentrations
of Mib, DHT, OH-Fl and Cx. MCF-7 and ZR-75 cell proliferation were
evaluated by [3H]thymidine incorporation analysis. Columns, mean of
three independent experiments each performed with triplicate samples
expressed as percent of control. (B) Bottom panel, Western Blot analysis
of ER beta expression in cells treated for 48 hours as indicated. GAPDH
was used as loading control. Upper panel, the histograms represent the
mean ± S.D. of three independent experiments in which band intensities
were evaluated in terms of optical density arbitrary units and expressed
as the percentage of the control assumed to be 100%. (C) Real-Time
RT-PCR for analyzing ER beta mRNA levels in cells treated as indicated.
Each sample was normalized to GAPDH RNA content. Data represent the
mean ± S.D. of values from three separate RNA samples expressed as
percentage of control assumed to be 100%. *, P <0.01 compared to
vehicle treated-cells.
Additional file 2: Figure S2. Knockdown of ER beta in MCF-7 cells.
Western blot analysis for ER beta in MCF-7 cells transfected with
non-specific siRNA (−) or targeted against human ER beta (100 nM)
for 48 hours. GAPDH was used as a loading control. LNCaP (+) was
used for positive control.
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